Salvia ceratophylla L. from South of Jordan: new insights on chemical composition and biological activities

• Autor(a) principal: Abu-Darwish, Mohammad Sanad
• Data de Publicação: 2020
• Outros Autores: Cabral, Célia, Ali, Zulfigar, Wang, Mei, Khan, Shabana I., Jacob, Melissa R., Jain, Surendra K., Tekwani, Babu L., Zulfiqar, Fazila, Khan, Ikhlas A., Taifour, Hatem, Salgueiro, Lígia, Efferth, Thomas
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/106496; https://doi.org/10.1007/s13659-020-00259-9
• topic: Lamiaceae; Essential oil; Chemical composition; Cytotoxicity; Anti-inflammatory activity; Neglected diseases

In Jordan, Salvia ceratophylla L. is traditionally used in the treatment of cancer, microbial infections, and urinary disorders. This study aimed: (1) to chemically characterize S. ceratophylla essential oil (EO) from South Jordan, by gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS); and (2) to evaluate in vitro the cytotoxic, anti-inflammatory, and antiprotozoal activities of the EO, it's predominant components, and the hexane (A), ethyl acetate (B), methanol (C) and crude-methanol extracts (D). The analysis revealed that the EO has 71 compounds, with linalool (54.8%) as main constituent. Only the hexane extract (A) showed some cytotoxic activity against SK-MEL, KB, BT-549, SK-OV-3, LLC-PK1 and VERO cells lines with IC50 between 60 and > 100 µg/mL. The EO inhibited NO production (IC50 90 µg/mL) and NF-κB activity (IC50 38 µg/mL). The extracts A, B, and D inhibited NO production and NF- κB activity with IC50 between 32 and 150 µg/mL. Linalool considerably inhibited NO production (IC50 18 µg/mL). The extracts tested did not exhibit antileishmanial activity. Regarding antitrypanosomal activity, the EO exhibited significant results with IC50 2.65 µg/mL. In conclusion, Jordan S. ceratophylla EO represents a rich source of linalool and bears a promising therapeutic potential for further antitrypanosomal drug development.